2-(1,3-Dioxo-3a,4,5,6,7,7a-hexahydroisoindol-2-yl)-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(1,3-Dioxo-3a,4,5,6,7,7a-hexahydroisoindol-2-yl)-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione
• 化学式: C₁₆H₂₀N₂O₄
• 分子量: 304.34
• InChiKey: DSENAHASHSAEJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  74.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
  申请人：Hruska A. Keith

  公开号：US20050272649A1

  公开（公告）日：2005-12-08

  The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP/BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.

  本发明提供了用于治疗受试者（尤其是哺乳动物受试者）慢性肾功能衰竭和其他肾脏疾病肾替代疗法的试剂和方法，以及用于预防和/或治疗的药物。这些方法涉及将血管紧张素转换酶（ACE）抑制剂或血管紧张素 II 受体拮抗剂（AIIRA）与一种或多种 OP/BMP 家族蛋白（形态发生素、形态发生素诱导剂或相应形态发生素受体的激动剂等）联合给药。本发明还提供了通过联合使用 ACE 抑制剂或 AIIRA 与这些形态发生因子诱导肾细胞的植入方法。
• CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE
  申请人：Curis, Inc.

  公开号：EP1578360A2

  公开（公告）日：2005-09-28
• US4310461A
  申请人：——

  公开号：US4310461A

  公开（公告）日：1982-01-12
• [EN] CONJOINT ADMINISTRATION OF MORPHOGENS AND ACE INHIBITORS IN TREATMENT OF CHRONIC RENAL FAILURE<br/>[FR] ADMINISTRATION CONJOINTE DE MORPHOGENES ET D'INHIBITEURS DE CONVERSION DE L'ENZYME DE L'ANGIOTENSINE POUR LE TRAITEMENT DE L'INSUFFISANCE RENALE CHRONIQUE
  申请人：CURIS INC

  公开号：WO2004019876A2

  公开（公告）日：2004-03-11

  The present invention provides reagents and methods for the treatment, and pharmaceuticals for use in the prevention and/or treatment, of chronic renal failure and other renal disorders in subjects (particularly mammalian subjects) renal replacement therapy. The methods involve the conjoint administration of ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one or more OP/BMP family of proteins (morphogens, or inducers of morphogens, or agonists of the corresponding morphogen receptors, etc.). The invention also provides methods for implantation of renal cells induced with the conjoint administration of ACE inhibitors or AIIRAs with those morphogens.